Pelage Pharmaceuticals with an absolute stunner of a molecule Chat 4/26/2026
PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity Pelage Pharmaceuticals' PP405 listed on Time Magazine's List of Best Inventions of 2025
Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.
community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
community Pelage Pharmaceuticals posted a tweet about PP405.
Pelage Pharmaceuticals' PP405 is discussed with skepticism about its effectiveness in hair regrowth, with some users expressing doubt and others hopeful but cautious. Treatments like finasteride are mentioned as current options, but there's a general sentiment that a cure for hair loss is not imminent.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
community Pelage Pharmaceuticals Phase 3 Trials for PP405 Start in September 2026
Pelage Pharmaceuticals is starting Phase 3 trials for PP405 in September 2026, with potential market release by 2030. Users discuss various hair loss treatments like minoxidil, finasteride, RU58841, kx, breezula, and gt20029, expressing hope for future hair restoration.
Related Research
6 / 6 results
research Recent Advances in Drug Development for Hair Loss
This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research PP405 in Alopecia: An Emerging Molecule worth Investigating
In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.
research Use of Vitamins and Minerals in the Treatment of Hair Loss: A Cross-Sectional Survey among Dermatologists in Saudi Arabia
This study found that a majority of dermatologists in Saudi Arabia believe in using vitamins and minerals to treat hair loss but emphasized the need for more research to confirm their effectiveness.
research A single-center, prospective, open-label, pilot study of the safety, local tolerability, and efficacy of ultraviolet-C (UVC) phototherapy for the treatment of great toenail onychomycosis
Trichoscopy is a helpful and quick method to diagnose hair loss without shaving.
research Eosinophilic Folliculitis in a Dog
This case report describes a 1-year-old Daschund with canine eosinophilic folliculitis whose symptoms improved following immunosuppressive therapy with glucocorticoids.